Compare NSSC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | ARDX |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2014 |
| Metric | NSSC | ARDX |
|---|---|---|
| Price | $40.90 | $6.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $48.17 | $15.14 |
| AVG Volume (30 Days) | 310.1K | ★ 4.0M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $181,621,000.00 | $2,607,000.00 |
| Revenue This Year | $13.63 | $37.75 |
| Revenue Next Year | $10.05 | $34.24 |
| P/E Ratio | $58.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.44 | $3.54 |
| 52 Week High | $47.61 | $8.40 |
| Indicator | NSSC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 57.38 |
| Support Level | $37.43 | $5.54 |
| Resistance Level | $44.43 | $8.23 |
| Average True Range (ATR) | 1.82 | 0.38 |
| MACD | -0.62 | 0.08 |
| Stochastic Oscillator | 20.27 | 57.37 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.